Bloomscape Founder and CEO Justin Mast joined Yahoo Finance Live to break down how Bloomscape is upending traditional garden centers.
Bloomscape Founder and CEO Justin Mast joined Yahoo Finance Live to break down how Bloomscape is upending traditional garden centers.
Everything you need to know ahead of the 93rd Academy Awards on Sunday.
The "Storage Infrastructure in India 2020: Market Insights, Trends, Opportunities and Outlook" report has been added to ResearchAndMarkets.com's offering.
Israel and Britain are exploring the possibility of opening a "green travel corridor" between them, Israel's Foreign Ministry said on Tuesday, citing the success of the two countries' vaccination drives. The issue was discussed at a meeting between Foreign Minister Gabi Ashkenazi and British Cabinet Office Minister Michael Gove in Jerusalem, an Israeli statement said. "We will promote, together with the UK, mutual recognition of vaccines in order to allow tourists and business people from both countries to safely return to their routines," the statement quoted Ashkenazi as saying.
Chelsea and Manchester City have Super League doubts, says executive
Image 1 Gold Leach Recoveries for all deposits Image 2 Changes in the kinetic index over ranges of cyanide concentration for six composites Highlights: Metallurgical testing has demonstrated above 50% Gravity Recoverable Gold and 95% overall gold recovery on most deposits.All deposits are amenable to treatment in a single processing facility.Composite samples from all deposits suggest the presence of coarse gold and show negligible amounts of deleterious elements, such as Arsenic, Antimony and Tellurium.A grade-recovery curve has been calculated for all deposits, which will be used for the upcoming PEA. Gold recovery is calculated as a function of head grade and includes typical plant losses.All deposits responded extremely well to multiple pre-concentration methods, with potential to enhance project value.Updated resource estimate is expected in Q2-2021 and PEA is expected in Q3-2021. TORONTO, April 20, 2021 (GLOBE NEWSWIRE) -- Probe Metals Inc. (TSX-V: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce positive results of the 2020 metallurgical test work program on its Val-d’Or East Project. The program consisted of mineralogy, physical property characterization, gravity, cyanidation and flotation tests. The main objective of the program was to assess gold recoveries by deposit and/or gold trend and to support the selection and design of the flowsheet for the Preliminary Economic Assessment (“PEA”). The results indicate that all deposits and gold trends are behaving similarly and that they can be treated in a single processing facility. They also indicate that gravity recoverable gold is high in all deposits (above 50% up to 72%) and that the overall gold recovery (gravity + leaching of gravity tails) is above 95% in all cases with the exception of Highway at 91%, which represents only 3% of the 2019 resource estimate. It was demonstrated that the leach gold recoveries can be correlated to head grade and a net gold recovery equation for use in the PEA was established which includes typical plant losses. In addition, the program has demonstrated that all deposits/gold trends are responding very well to other pre-concentration methods like flotation, continuous gravity separation and ore sorting which provides additional opportunities to enhance project value. The test work program was performed at Corem facilities in Quebec City. David Palmer, President and CEO of Probe, states: “The metallurgical test work demonstrates once again how the Val-d’Or East project performs beyond expectations and confirms that it is an excellent candidate for development. We have already shown the area’s ability to host ounces and now we are building confidence in the development potential of those ounces. We have hit a number of key milestones as we advance the project towards the PEA, which includes strong geotechnical results demonstrating good rock stability; favourable environmental characteristics of host rocks; and now confirmation that all of the mineralized materials not only have high gravity and overall recoveries, but all can be processed together in one mill. These characteristics will provide initial cost savings during construction as well as adding further value downstream during a production scenario.” Yves Dessureault, COO of Probe, states: “These results are a very important milestone for the Val-d’Or East project. We have gone from a concept of multiple deposits feeding a central mill to actually demonstrating it with the metallurgical test work results. All deposits have the same type of response in Gravity and Leaching. The Gravity Recoverable Gold is coarse to very coarse and we have been able to model most of the resource with a single grade-recovery curve/equation, with potential for future enhancements. Lower strip ratios, less costly waste rock storage, more efficient milling and reduced infrastructure costs are just a few of the benefits we are seeing in the development work, and all should contribute to a more robust bottom line for the project. In my experience, it would be difficult to find a mineral resource that was easier to process than what we have at Val-d’Or East.” Metallurgical Test work Program – Objectives The goal of the 2020 metallurgical test work program was to improve upon the historical recoveries and establish recoveries on the deposits where no information was available. An additional objective was to build the metallurgical knowledge base to support the design of the PEA and the selection of the process plant flowsheet. The program consisted of mineralogy, physical property characterization, gravity amenability tests (GAT), gravity recoverable gold tests (GRG), cyanidation with grind size assessment and flotation. Eight composites were created, either from drill core intervals or from products generated in the 2018 ore sorting test program. Composite were created from drill core intervals for New Beliveau, Courvan, Monique, Highway and North-Zone (a total of five composites). All composites assembled from drill core intervals were spatially selected to be representative of both the type of mineralization and the average head grade of the resource. In addition, three New Beliveau composites were created from ore sorting products. A complete summary is provided below: New Beliveau, a total of 4 composites One whole-ore composite from drill core samplesTwo composites representing ore sorting concentrates, a high- and a low-grade composite.One whole-ore composite created from ore sorting products (concentrates and tails) North Zone, one whole-ore composite from drill core samplesHighway, one whole-ore composite from drill core samplesCourvan, one whole-ore composite from drill core samplesMonique, one whole-ore composite from drill core samples Main Results Mineralogy The mineralogical and chemical analyses performed on the eight composites suggest the presence of coarse gold in every composite sample. The analyses of deleterious elements, such as Arsenic, Tellurium and Antimony were near to or under the detection limit for all samples. All samples were mainly composed of quartz, micas, feldspars and carbonates with varying proportions. Pyrite was the main sulfide mineral detected and accounted for 1.6 to 3.8% by weight of all samples. Pyrite was always very well liberated. Crushing and Grinding Testing For the 2020 metallurgical program, only New Beliveau samples went through a detailed comminution test work program. Work included Bond Crusher Work Index (CWI), Bond Rod Mill Work Index (RWI), Bond Ball Mill Work Index (BWI), Bond Abrasion Index (AI) and finally SAG mill comminution test (SMC). The composites were considered to be hard to very hard for CWI (between 16.9 and 20.0 kWh/t) and the SMC tests (A x b between 29.3 to 37.2), both are measurements of resistance to impact breakage. Samples tested showed medium hardness for the RWI and BWI with average values of 12.9 kWh/t and 11.6 kWh/t respectively, and non-abrasive with an average Abrasion Index (AI) of 0.131g. Pre-Concentration Testing The Company has continued its work on pre-concentration alternatives to the standard free milling flowsheet. In addition to the ore sorting test work done in 2018 (see Press Release of May 20th, 2020 for test results), flotation and continuous gravity separation were tested as part of the 2020 metallurgical test work program. Gravity Amenability Tests (GAT) were completed on all composites. The GAT test is a standard test to assess the potential of using continuous gravity separation technology for the separation of heavier minerals from the gangue material. The results show that all deposits are highly amenable to gravity separation with a gold recovery ranging from 57% to 73% for whole ore material and approximately 92% for ore sorting concentrate with an 8% mass yield. These recoveries increase to between 87% to 98% when the mass yield is increased to approximately 18%. Preliminary flotation test work was performed on a New Beliveau composite. The sample was first subjected to gravity concentration (the GRG test described in next section) and the gravity tails was then floated to recover sulfides and gold. With a coarse grind of 80% passing (P80) = 125 µm, 99.1% of the gold reported to the flotation concentrate with mass yields of between 6 to 8%. These pre-concentration alternatives will continue to be evaluated by the Company following the PEA. Gravity Testing (GRG) Four whole-ore composites (New Beliveau, Highway, Courvan and Monique) and one ore sorting concentrate composite (New Beliveau OSC) were tested with the Gravity Recoverable Gold (GRG) protocol to determine their amenability to gravity concentration. The results are showing that the GRG is coarse to very coarse, and are also indicating very good gold recoveries. At a grind size of approximately 45-50% passing 75µm (equivalent 80% passing 226 µm), gold recoveries were respectively 50.7%, 54.2%, 69.4%, 71.9% for the New Beliveau, Highway, Monique and Courvan whole ore composites, and was 55.2% for the New Beliveau ore sorting concentrate composite. The GRG value does not directly predict or correlate gold recovery results from a closed-circuit milling operation. It is indicative of gravity gold amenability and in this scenario all samples would benefit from the inclusion of a gravity circuit. Leach Testing Leach test work was performed on the composites’ GRG tailings. A first series of bottle roll tests was executed to assess the impact of grind size. The results are shown in the following figure and based on these results, the target grind of 80% passing 80 µm was selected. Image 1 Gold Leach Recoveries for all deposits https://www.globenewswire.com/NewsRoom/AttachmentNg/c408b2dd-d64e-4cc6-bb8a-2d6fd658ec2b The leach and gold dissolution kinetics were then studied by Corem using their proprietary methodology. This methodology facilitates and expedites the finding of the optimal leaching conditions. A first batch of tests were done with cyanide only and then a second series was done with the addition of lead nitrate. As an example, the attached figure shows the changes in the kinetic index over ranges of cyanide concentration for six composites. The methodology shows that the optimum cyanide concentration is around 700 ppm NaCN, above which no further gain can be observed. Image 2 Changes in the kinetic index over ranges of cyanide concentration for six composites https://www.globenewswire.com/NewsRoom/AttachmentNg/f8407934-f88a-473d-89cd-64100fd9f328 Following the investigation with the Corem proprietary technology, a few stirred tank reactor leaching tests were performed to validate the results and obtain reagents consumptions. Gold Recoveries The test work has demonstrated that a PEA flowsheet based on grinding to a target of 80% passing 80 microns followed by gravity and then leach of the gravity tails would give very good performance. The combined gold recoveries obtained in the metallurgical test work program are shown in the table below (Note: The gravity separation concentrate has been assumed in the calculations to be 100% recoverable through intensive leach and tailings recirculation). CompositeFinal grind size (P80, µm)Head calc'd(g/t)Final tails(g/t)Gold distribution (%)GRGGold leachedGold tailOverall recoveryNew Beliveau OSC727.060.19655.242.02.897.2New Beliveau793.400.15950.744.64.795.3Highway801.850.154188.8.131.521.7Courvan712.910.06471.925.92.297.8Monique701.870.04869.428.02.697.4 Leach results above are based on 48 hours and a slurry density of 40% solids. Sodium cyanide consumption was between 0.41 and 0.73 kg/t while lime consumption varied from 0.60 to 2.57 kg/t. Recoveries represent maximum metal extractions and do not include typical plant losses or scale up of gravity recoverable gold for plant operating conditions. PEA recoveries For the PEA, further analysis was performed to assess the differences between deposits, the impact of grind and head grade. It can be concluded that all deposits are behaving similarly and can be grouped together, with some adjustments for the Highway deposit, which is a small percentage of the overall resource. Due to the coarse to very coarse nature of the GRG, the process design criteria will be based on treating 90% of the grinding mill recirculating load through the gravity circuit, with modeling indicating an average of 55% gravity gold recovery under those conditions. This result aligns well with the 50% gravity recovery achieved by Cambior when they mined the Beliveau deposit from 1989 to 1993. The PEA will conservatively assume 50% gravity recovery. In addition, the leach test results were analyzed and reviewed to establish leach gold recoveries. It was identified that the New Beliveau, North Zone, Courvan and Monique deposits have similar responses and that their leach gold recoveries can be correlated to head grade. The following relationship has been established from the test results: Leach gold recovery (in %) = 95.07 – 3.74/Head grade (in g/t) For Highway, the equation is adjusted to: Leach gold recovery (in %) = 95.07 – 8.74/Head grade (in g/t) When the gravity and the leach gold recoveries are combined, and then reduced with the typical plant losses or impact of scale up of gravity recoverable gold for plant operating conditions (typically about 0.8%), the following net recoveries are obtained: Head grade (g/t Gold) New Beliveau (whole ore and ore sorting concentrate), Courvan, Monique &North Zone deposits (Gold Recovery %) Highway Deposit (Gold Recovery %) 0.487%75%0.791%84%1.093%88%1.595%91%2.095%92%2.595%93%3.095%94% Next steps Following the PEA, a new metallurgical program will be defined to further investigate the selected process route(s) and improve upon the current knowledge base developed through the 2020 metallurgical program and potentially further improve reagent costs and gold recoveries. Qualified PersonsThe scientific and technical content of this press release has been reviewed, prepared and approved by Mr. Yves Dessureault, P.Eng., COO and was reviewed and approved by Tommaso Roberto Raponi, P.Eng. each of whom is a "Qualified Person" as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101"). Mr. Raponi is a consultant of Ausenco Engineering Canada Inc. (“Ausenco”) and is considered to be “independent” of Probe for purposes of section 1.5 of NI 43-101. About Corem:Corem is a center of expertise and innovation in mineral processing with the largest concentration of resources dedicated to R&D in this field in Canada. Corem is a not-profit organization that works closely with its members, its clients and its partners to improve competitiveness and to reduce environmental impact through the industrialization of innovative solutions. Corem has extensive equipment and infrastructure, including a pilot plant and laboratories for mineralogy, mineralogy and hydrometallurgy, that allow for innovation. For more information, please visit: corem.qc.ca About Ausenco:Ausenco is a global diversified engineering, construction and project management company providing consulting, project delivery and asset management solutions to the resources, energy and infrastructure sectors. Ausenco’s experience in gold projects ranges from conceptual, pre-feasibility and feasibility studies for new project developments to project execution with EPCM and EPC delivery. Ausenco is currently engaged on a number of global projects with similar characteristics and opportunities to the Val-d’Or East Project. About Probe Metals:Probe Metals Inc. is a leading Canadian gold exploration company focused on the acquisition, exploration and development of highly prospective gold properties. The Company is committed to discovering and developing high-quality gold projects, including its key asset the Val-d’Or East Gold Project, Quebec. The Company is well-funded and controls a strategic land package of approximately 1,000-square-kilometres of exploration ground within some of the most prolific gold belts in Quebec. The Company was formed as a result of the sale of Probe Mines Limited to Goldcorp in March 2015. Newmont currently owns approximately 11.6% of the Company. On behalf of Probe Metals Inc., Dr. David Palmer, President & Chief Executive OfficerFor further information: Please visit our website at www.probemetals.com or contact: Seema SindwaniDirector of Investor Relationsinfo@probemetals.com+1.416.777.9467 Forward-Looking Statements Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This News Release includes certain "forward-looking statements" which are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements, exploration results, potential mineralization, the estimation of mineral resources, exploration and mine development plans, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate First Nations and other indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, an inability to predict and counteract the effects of COVID-19 on the business of the Company, including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restriction on labour and international travel and supply chains, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Xerox Holdings Corporation (NYSE: XRX) announces 2021 first-quarter results.
Luka Doncic is one of the best players in the league, but could end up elsewhere if he doesn’t get enough help in Dallas.
Illumina disagrees with the European Commission’s Directorate-General for Competition’s decision to review Illumina’s acquisition of GRAIL.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has notified the Company in a letter that it has placed a clinical hold on the proposed Phase 2 clinical trial of KVD824.
Magellan Healthcare is offering resources and programs to support individuals and families in honor of Mental Health Month in May.
Global, a multinational supplier of over 70+ FDA Approved Diagnostic Tests, attains breakthrough on rising neurological disease testing. San Clemente, CA, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Global WholeHealth Partners (OTC:GWHP) now has the means to identify and test for Dementia using a Micro-Well Reader or Lateral Flow Test to measure the certain brain enzymes during the data collection process used in a positive diagnosis. This was disclosed in an 8K filed March 21, 2021 which can be found by clicking here. "This could simply be described as nothing short of a Medical Breakthrough in Dementia Diagnostic Testing.” -- said Charles Strongo, CEO of Global WholeHealth Partners, Corp (OTC:GWHP). “We believe this announcement couldn’t come at a better time for us as we are partnering with Nunzia Pharmaceutical and their products for Neurological disorders,” said Mr. Strongo. “Nunzia Pharmaceutical with nutraceutical for anxiety and stress based on their patented formula and their pharmaceutical drug they are planning on bringing through the FDA, which specifically works on the Hippocampus part of the brain, dealing with stress, memory, and fine motor skills are a perfect fit for Global’s diagnostic tests,” says Mr. Strongo. Nutritional deficiencies: Not drinking enough liquids (dehydration); not getting enough thiamin (vitamin B-1), which is common in people with chronic alcoholism; and not getting enough vitamins B-6 and B-12 in your diet can cause dementia-like symptoms. Copper and vitamin E deficiencies also can cause dementia symptoms: https://www.mayoclinic.org/diseases-conditions/dementia/symptoms-causes/syc-20352013. “Early detection for Dementia disease is not only crucial for patients and their quality of life, but this data is also used by researchers to seek out commonalities, causes and hopefully cures,” commented Strongo. Mr. Charles Strongo, the Chairman and CEO of Global WholeHealth Partners Corp, said, "The Company's goal is to offer the fastest and most reliable in-vitro diagnostic tests on the market, while keeping ahead in R&D, by offering FDA Approved Troponin I Whole Blood, Influenza A & B, and Strep A. The Company also has international testing, which is not sold in the USA, with an FDA Certificate of Exportability (2260-11-2019) for tests like ZIKA, Rapid Ebola, Rapid Dengue Fever Antibody, and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests." GWHP develops, manufactures, and markets in vitro diagnostic (IVD) tests for OTC, or consumer-use as well as professional rapid diagnostic point-of-care (POC) test kits for hospitals, physicians’ offices, and medical clinics in the US and abroad. The Company has the capacity to deliver hundreds of thousands of tests, and can ramp up to 1 million tests per day. Currently, the Company has 56 products FDA approved and many are Approved for OTC use, and 9 POC products approved by the FDA. Media Contact: Name: Charles Strongo, CEO, Global WholeHealth Partners Corp. Email: Sales@gwhpcorp.com Phone for Sales: 949-324-6691 www.gwhpcorp.com This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Fifth Third Bancorp (NASDAQ®: FITB):
Hear what the civil rights attorney had to say in Charlotte after learning he’d prevailed in the Swann v. Charlotte-Mecklenburg schools case.
Nightfood Ice Cream NightFood Holdings, Inc. Tarrytown, NY, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nightfood, Inc. (OTCQB: NGTF), the better-for-you snack company targeting the $50 billion Americans spend annually on nighttime snacks, today announced that Nightfood sleep-friendly ice cream is rolling into over 1,000 Walmart stores across the country. “The confidence that Walmart is showing in Nightfood is amazing,” commented Nightfood COO Jenny Mitchell. “We’re rolling into more than double the Walmart store count we were told to anticipate back in the fall.” The sleep-friendly ice cream, which is also the American Pregnancy Association’s recommended ice cream for pregnancy cravings, will be available in more than a dozen Walmart regions, with official on-shelf placement starting today. The five flavors selected for initial introduction are Cookies n’ Dreams, After Dinner Mint Chip, Bed and Breakfast, Cold Brew Decaf, and Pickles For Two. The large majority of locations will offer three or more flavors. In addition to hundreds of Walmart stores in existing Nightfood regions such as Illinois, Texas, the Carolinas, and the Pacific Northwest, Walmart is establishing Nightfood retail distribution in markets like San Jose, Oakland, San Francisco, Sacramento, Reno, Los Angeles, San Diego, Bentonville, Little Rock, Tampa, Orlando, and more. The more than one thousand Walmart locations adding Nightfood are live on the Nightfood store locator as of this morning. While Nightfood started appearing on some Walmart shelves last week, the introduction was expected to occur between April 19 and April 30 in most stores. “Launching into Walmart is a tremendous step in bringing better nighttime snacking, and better sleep, to nighttime snackers across the country,” commented Nightfood CEO Sean Folkson. “Our shareholders know the confidence I have that the sleep-friendly nutrition category is coming. Pepsi recently launched their first ever nighttime relaxation drink, and Unilever just announced a year-long study to explore how diet can improve sleep through the gut-brain axis. Sleep-friendly nutrition is a category with massive potential. It’s in its infancy right now, and we are proud to be leading the way.” Nightfood’s Walmart introduction more than doubles the store count for the award-winning ice cream brand to approximately 1,900 retail locations across the United States. The Company announced earlier today that it successfully completed a financing round totaling $4,500,000. Those funds allowed the company to retire all outstanding convertible debt while also providing operating capital for Management's 2021 growth plan. About Nightfood Holdings: Nightfood Holdings, Inc. (OTC: NGTF), owns Nightfood, Inc. and MJ Munchies, Inc. Nightfood has expanded distribution for its ice cream into major divisions of the largest supermarket chains in the United States: Kroger (Harris Teeter), Albertsons Companies (Jewel-Osco and Shaw’s and Star Markets), and H-E-B (Central Market) as well as Lowe’s Foods, Rouses Markets, and other independent retailers. On February 23, 2021, the Company announced it has secured distribution in Walmart. Nightfood won the 2019 Product of the Year award in the ice cream category in a Kantar survey of over 40,000 consumers. Nightfood was also named Best New Ice Cream in the 2019 World Dairy Innovation Awards. Nightfood has been endorsed as the Official Ice Cream of the American Pregnancy Association and is the recommended ice cream for pregnant women. There are approximately 3,000,000 pregnant women in the United States at any given time, and ice cream is the single most-widely reported pregnancy craving. With more calcium, magnesium, zinc, prebiotic fiber, and casein protein, less sugar and a lower glycemic profile than regular ice cream, Nightfood has been identified as a better choice for expectant mothers. Nightfood is not just for pregnant women. Over 80% of Americans snack regularly at night, resulting in an estimated 700M+ nighttime snack occasions weekly, and an annual spend on night snacks of over $50 billion dollars, the majority of it on options that are understood to be both unhealthy, and disruptive to sleep quality. Nightfood was formulated by sleep and nutrition experts with ingredients that research suggests can support nighttime relaxation and better sleep quality. Scientific research indicates unhealthy nighttime cravings are driven by human biology. Willpower is also weakest at night, and stress is another contributing factor. A majority of night snackers report feeling both guilty and out-of-control when it comes to their nighttime snacking. Because unhealthy night snacking is believed to be biologically driven, and not a trend or a fad, management sees significant opportunity in pioneering the category of nighttime-specific snacks for better sleep. MJ Munchies, Inc. was formed in 2018 as a new, wholly owned subsidiary of Nightfood Holdings, Inc. to capitalize on legally compliant opportunities in the CBD and marijuana edibles and related spaces. The Company is seeking licensing opportunities to market such products under the brand name “Half-Baked”, for which they’ve successfully secured trademark rights. Questions can be directed to investors@Nightfood.com Management also encourages Nightfood shareholders to connect with the Company via these methods: E-mail: By signing up at ir.nightfood.com, investors can receive updates of filings and news releases in their inbox. Telegram: There is now a live, interactive Telegram group which interested parties can join to reach team members and discuss Nightfood. Ask questions, learn more about the company and discuss future prospects. Join the Telegram Group Here: https://t.me/NightfoodHoldings YouTube: The company has established a new YouTube series which will feature weekly videos with team members, insights into latest industry developments, and provide a behind the scenes look at the latest company developments. Click here to subscribe to Nightfood’s YouTube channel. Forward Looking Statements: This current press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission. Media Contact: Tim Sullivan media@Nightfood.com 732-816-0239 Investor Contact: Stuart Smith investors@Nightfood.com 888-888-6444, x3 Attachment Nightfood Ice Cream
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on Tuesday, May 4, 2021 at 8:00 a.m. ET to announce first quarter 2021 financial results and discuss recent business updates.
Soma Gold Corp. (TSXV: SOMA) (WKN: A2P4DU) (OTC: SMAGF) (the "Company" or "Soma") is pleased to announce new drilling and channel sampling results for the on-going exploration program at the Company's Zara property in Antioquia, Colombia.
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe. “This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is the result of the continued dedication of GW and the physician and patient communities to address this serious unmet medical need,” said Justin Gover, GW’s Chief Executive Officer. “We now look forward to working with each European member state to make EPIDYOLEX® available to appropriate patients across Europe, as quickly as possible.” Dr. Volker Knappertz, GW’s Chief Medical Officer, said, “We are excited by the news of this approval by the European Commission and the benefits EPIDYOLEX could bring to the community. The clinical data supporting EPIDYOLEX in TSC provides hope of a better quality of life for patients. This medicine provides more choice for physicians managing seizures associated with TSC and has the potential to benefit the thousands of patients who do not respond to the current standard of care.” Professor Alexis Arzimanoglou, Coordinator of the European Reference Network for Rare and Complex Epilepsies ERN EpiCARE (University Hospitals of Lyon, France), added, “Those suffering from TSC and those involved in their care will welcome this European approval. Given the demonstrated efficacy and safety profile of EPIDYOLEX, this important development could offer a much-needed treatment option to those most in need.” The approval is based on data from a positive Phase 3 safety and efficacy study evaluating 25 mg/kg/day of GW’s cannabidiol. The study met its primary endpoint, which was the reduction in seizure frequency compared to baseline of cannabidiol vs placebo, with seizure reduction of 49% in patients taking cannabidiol 25 mg/kg/day compared with 27% for placebo (p=0.0009). All key secondary endpoints were supportive of the effects on the primary endpoint. The safety profile observed was consistent with findings from previous studies, with no new safety risks identified. TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.4 GW’s cannabidiol was originally approved by the European Medicines Agency (EMA) in September 2019 under the tradename EPIDYOLEX® as an adjunctive therapy for seizures associated with Lennox-Gastaut Syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. The EC decision is valid in all 27 countries of the European Union, alongside Norway, Iceland and Liechtenstein. ADDITIONAL INFORMATION About GW Pharmaceuticals plcGW Pharmaceuticals (GW), and U.S. subsidiary Greenwich Biosciences, is a UK-based global biopharmaceutical company that has established a world-leading position in cannabinoid science and medicine. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation. GW’s pioneering work has led to the regulatory approval of world first, potentially life improving, cannabis-based medicines. Our continued dedication has resulted in the treatment of thousands of patients with our medicines around the world. For further information, please visit www.gwpharm.co.uk About EPIDIOLEX®/EPIDYOLEX® (cannabidiol)EPIDIOLEX®/EPIDYOLEX® (cannabidiol), the first prescription, plant-derived cannabis-based medicine approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. and the European Commission (EC) for use in Europe, is an oral solution which contains highly purified cannabidiol (CBD). In the U.S., EPIDIOLEX® is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome or Tuberous Sclerosis Complex (TSC) in patients one year of age and older. EPIDIOLEX® has received approval in the European Union under the tradename EPIDYOLEX® for adjunctive use in conjunction with clobazam to treat seizures associated with LGS and Dravet syndrome in patients two years and older, and for adjunctive use to treat seizures associated with TSC, in patients two years of age and older. EPIDYOLEX® has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of seizures associated LGS, Dravet syndrome, and Tuberous Sclerosis Complex (TSC). About Tuberous Sclerosis Complex (TSC)Tuberous Sclerosis Complex (TSC) is a rare genetic condition that has an estimated prevalence in the EU of 10 in 100,000.5 The condition causes mostly benign tumours to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs and is a leading cause of genetic epilepsy.4,5 The onset of epilepsy in TSC often occurs in the first year of life with patients initially suffering from predominantly focal seizures or infantile spasms. It is associated with an increased risk of autism and intellectual disability.1 The severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.6,7 EnquiriesAll investor and media email@example.com GW Pharmaceuticals plc Scott Giacobello, Chief Financial Officer+1 760 795 2200 UK, EU and ex-U.S. media enquiries FTI Consulting Michael Trace / Ben Atwell+44 (0)203 727 1000 U.S. media enquiries Kristen Cardillo, Corporate Communications+1 760 579 6628 Nabbout R, Belousova E, Benedik MP, et al. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open. 2019 Mar; 4(1): 73–84.2 Boston Children’s Hospital. https://www.childrenshospital.org/conditions-and-treatments/conditions/t/tuberous-sclerosis-tsc/symptoms-and-causes. Accessed March 2021.Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010;51(7):1236–41.NIH Tuberous Sclerosis Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Tuberous-Sclerosis-Fact-Sheet.Prevalence and incidence of rare diseases: Bibliographic data. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdfTS Alliance Website. https://www.tsalliance.org/. Accessed March 2021de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.
On April 13, Novocure (NASDAQ: NVCR) stock jumped after the company received a green light to accelerate a pivotal phase 3 study. The investigation involves its medical device, Optune, to treat advanced-stage non-small-cell lung cancer (NSCLC). Optune is a portable device that applies small alternating electric currents to cancer cells in the patients' bodies, disrupting their replication process and causing cell death.
Synovus Financial Corp. (NYSE: SNV) today reported financial results for the quarter ended March 31, 2021.
DALLAS, April 20, 2021 (GLOBE NEWSWIRE) -- In advance of meetings with investors scheduled to take place this week, Dave & Buster's Entertainment, Inc., (NASDAQ:PLAY), ("Dave & Buster's" or "the Company"), an owner and operator of entertainment and dining venues, today provided an update on business trends through April 18, 2021, representing the first 11 weeks of its 13 week fiscal first quarter, which began February 1, 2021 and ends May 2, 2021. The Company began the first quarter with 107 open stores, or approximately 76% of its total store base. As of April 18, the Company had reopened a total of 138 stores, or approximately 98% of its 141 store base, including 11 New York stores which opened in March and 15 California stores that reopened between mid-March and mid-April. Most locations continue to operate under reduced hours and capacity limitations, including 7 stores that are restricted to food and beverage operations only. As of April 18, through the first eleven weeks of the first quarter: Overall comparable store sales were -38% compared to 2019 levels1Sales at fully operational comparable stores achieved 81% of 2019 levels1Quarter-to-date sales totaled approximately $228 million with two weeks remaining in the period Based on these preliminary results and assuming a normal seasonal sales deceleration and no other unforeseen factors over the remainder of the quarter, the Company now expects first quarter sales to total between approximately $252 million and $257 million, compared to the Company’s prior expectations of $210 million to $220 million. Chief Executive Officer Brian Jenkins said, “We have been very pleased with our recently reopened stores in New York and California, which have produced some of our strongest early sales recoveries to date. Their performance, in tandem with economic stimulus, expanding vaccines and a favorable Easter and spring break shift, has accelerated sales recovery trends across our entire store base.” The Company expects to report final first quarter 2021 financial results in early June 2021. 1The Company believes that calculating 2021 comparable store sales against 2019 results provides a more meaningful comparison vs. against COVID-affected 2020 results. About Dave & Buster’s Entertainment, Inc. Founded in 1982 and headquartered in Dallas, Texas, Dave & Buster's Entertainment, Inc., is the owner and operator of 141 venues in North America that combine entertainment and dining and offer customers the opportunity to "Eat Drink Play and Watch," all in one location. Dave & Buster's offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. Dave & Buster's currently has stores in 40 states, Puerto Rico, and Canada. Forward-Looking Statements The Company cautions that this release contains forward-looking statements, including, without limitation, statements relating to the impact on our business and operations of the global spread of the novel coronavirus outbreak. These forward-looking statements involve risks and uncertainties and, consequently, could be affected by the uncertain and unprecedented impact of the coronavirus on our business and operations and the related impact on our liquidity needs; our ability to satisfy covenant requirements under our revolving credit facility; the duration of government-mandated and voluntary shutdowns; the speed with which our stores safely can be reopened and the level of customer demand following reopening; the economic impact of the coronavirus and related disruptions on the communities we serve; our overall level of indebtedness; general business and economic conditions, including as a result of the coronavirus; the impact of competition; the seasonality of the Company's business; adverse weather conditions; future commodity prices; guest and employee complaints and litigation; fuel and utility costs; labor costs and availability; changes in consumer and corporate spending, including as a result of the coronavirus; changes in demographic trends; changes in governmental regulations; unfavorable publicity, our ability to open new stores, and acts of God. Accordingly, actual results may differ materially from the forward-looking statements, and the Company therefore cautions you against relying on such forward-looking statements. Dave & Buster's intends these forward-looking statements to speak only as of the time of this release and does not undertake to update or revise them as more appropriate information becomes available, except as required by law. *Non-GAAP Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, the Company uses the following non-GAAP financial measures: EBITDA, EBITDA margin, Adjusted EBITDA, Adjusted EBITDA margin, Store operating income before depreciation and amortization, and store operating income before depreciation and amortization margin (collectively the "non-GAAP financial measures"). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures used by the Company in this press release may be different from the measures used by other companies. For Investor Relations Inquiries:Scott Bowman, CFODave & Buster’s Entertainment, Inc.firstname.lastname@example.org